StockUS listing USTMDXNASDAQHealthcareQuality Compounder

TransMedics Group Inc(TMDX) Stock Analysis | Healthcare

USD --+0.00%
Reward74High
Risk72High
75%Data
Strong 20% profit margin · Revenue growing 41% YoY
USD —+0.00 (+0.00%) Previous close · NASDAQ
Market cap 3.17Bn
Reward Ratingⓘ74 High reward assessment · 75% data coverage
Top 10% of stocksView factors
Risk Ratingⓘ72 High risk assessment
Risk factors availableUnlock details

Educational tool only – Scores are based on historical data and financial metrics for informational purposes. This is not financial advice or a recommendation to buy or sell any security. Always conduct your own research or consult a qualified financial adviser.

Educational tool only · More
Limited data coverage
We don't have enough public data on TMDX to score it reliably yet — Reward, Risk, Forecasts and Dividends tabs aren't available for this stock. The price chart and basic profile are still shown.
OTC / ADR stock — scores and fundamentals use data tagged in USD by our provider. The issuer may report in a different home currency (e.g. JPY), so treat figures as directional rather than precise.
Not available yet for this stock
The overview tab requires data we don't have for this stock yet. The price chart is the most reliable view we have — try the Chart tab.
Earnings Ex-dividend

Market Performance

Stock returned +10.0% over the past year, broadly in line with market conditions.

What is TransMedics Group Inc?

, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally.

AI Brief Pro

The brief on TransMedics Group Inc

The story behind the price, the case for and against, and what could go wrong. Open a part to read it.

What is TransMedics Group Inc?

, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company provides Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. The company is listed on the NASDAQ in USA, operating in the Healthcare sector, with a market capitalisation of 3.17B, and a P/E ratio of 24.9x.

Financial Highlights

Investment Breakdown

Growth
Revenue and earnings growing steadily, indicating improving operating performance.
Profitability
Strong margins and consistent earnings support financial stability.
Risk
Moderate volatility with meaningful macro and earnings sensitivity.
Valuation
Valuation appears fair relative to current fundamentals.

OpenBook Logo Analysis

Reward: High (74)

Similar stocks to compare

A short list of Medical Devices names that are close enough in size to make side-by-side comparison useful.

Company Information
SectorHealthcare
IndustryMedical Devices
P/E Ratio24.8992
Beta2.096
Insider Activity
12M windowBearish
Shares soldShares bought
0-3months
0
0
3-6months
0
0
6-9months
616,205 shares
$2.4M
0
9-12months
38,920 shares
$1.3M
0